New Cost Impact Model Highlights Potential Benefits of Monthly Injectable Buprenorphine

Study finds monthly injectable treatment could reduce staffing burdens for opioid addiction care providers

Mar. 31, 2026 at 3:27pm

Got story updates? Submit your updates here. ›

A ghostly, translucent X-ray image of a human arm with a glowing, pulsing vein representing the flow of medication, conceptually illustrating the internal biological mechanisms of addiction treatment.A new cost analysis finds monthly injectable addiction treatments could ease the operational burdens on opioid care providers.Richmond Today

Indivior Pharmaceuticals has published a new cost impact model that examines the potential benefits of using monthly injectable buprenorphine to treat opioid addiction. The model suggests this treatment approach could help reduce staffing burdens and associated costs for care providers compared to daily oral medication.

Why it matters

Opioid addiction remains a major public health crisis, and care providers are often strained by the time and resources required to manage daily dosing of oral medications. If monthly injectable buprenorphine can provide an effective alternative that eases these operational challenges, it could improve access to addiction treatment and patient outcomes.

The details

Indivior's cost impact model analyzed the potential savings that monthly injectable buprenorphine could provide compared to daily oral medication. The model found that the reduced staffing needs for administering and monitoring monthly injections versus daily pills could lead to significant cost savings for care providers.

  • The cost impact model was published on March 31, 2026.

The players

Indivior Pharmaceuticals, Inc.

A pharmaceutical company that develops and markets medications for the treatment of opioid addiction and other substance use disorders.

Got photos? Submit your photos here. ›

The takeaway

As the opioid crisis continues, innovative treatment approaches that can improve access and reduce provider costs will be crucial. This analysis suggests monthly injectable buprenorphine may be one such solution worth further exploration.